The first US generic version of GlaxoSmithKline’s (GSK’s) Advair Diskus (fluticasone/salmeterol) will hit the market by the end of February with the launch of Mylan’s Wixela Inhub, the generics firm has revealed.
Mylan Gears Up To Launch US Advair Rival This Month
Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.
